Recent work has demonstrated the exact mechanism by which CALR causes the MPN phenotype, where the mutant proteins interact with the thrombopoietin receptor (MPL) and directly lead to dimerization and activation of JAK2 28, 29, 30. This evidence concerns the gene MPL and myeloproliferative neoplasm.